Pharma Pioneer

Genenta's Success in Reprogramming GBM Tumor Microenvironment Opens New Paths for Solid Tumor Treatments

29 May 2024
2 min read

Genenta Science, a clinical-stage biotech firm specializing in immuno-oncology, has made significant progress in its Phase 1/2 clinical trial for Temferon™, a cell-based therapy targeting solid tumors. The company has completed dosing for the first patient in Cohort 8, marking the final stage of the dose-ranging portion of the trial for patients with newly diagnosed uMGMT Glioblastoma Multiforme (GBM). So far, no dose-limiting toxicities have been observed in the 22 patients treated, and Temferon-derived cells have been detected in the bloodstream for over two years post-infusion.
Preliminary results for uMGMT patients, the most aggressive form of GBM, show a 2-year Overall Survival rate of 25%, surpassing the historical rate of 14% to 18% for patients receiving standard care. Genenta anticipates releasing the primary Phase 1 data by mid-2024.
Dr. Luigi Naldini, a co-founder of Genenta, suggests that Temferon has the potential to reprogram the Tumor Microenvironment and activate immune responses. Carlo Russo, the company's CMO, highlighted a patient who survived over three years with the treatment, indicating its potential for various solid tumors. Pierluigi Paracchi, CEO of Genenta, emphasized the technology's ability to prevent systemic toxicity.
Temferon is based on gene transfer into autologous hematopoietic stem/progenitor cells to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages. It is designed to induce a durable immune response and avoid systemic toxicity, addressing key challenges in immuno-oncology.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Belhaven Biopharma Reveals Promising Nasdepi Trial Outcomes: A Needle-Free Epinephrine Solution for Severe Allergies
Pharma Pioneer
2 min read
Belhaven Biopharma Reveals Promising Nasdepi Trial Outcomes: A Needle-Free Epinephrine Solution for Severe Allergies
29 May 2024
Belhaven Biopharma announced promising results from its Phase 1 clinical trial of Nasdepi, a nasal dry powder epinephrine device for treating anaphylaxis due to severe allergic reactions.
Read →
FDA Approves Hemogenyx's Phase I HEMO-CAR-T Trials
Pharma Pioneer
3 min read
FDA Approves Hemogenyx's Phase I HEMO-CAR-T Trials
29 May 2024
Hemogenyx Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) to commence Phase I clinical trials for its innovative HEMO-CAR-T treatment for acute myeloid leukemia (AML).
Read →
HMB-001 Phase 1 Success in Glanzmann Thrombasthenia Showcased at EAHAD 2024
Pharma Pioneer
2 min read
HMB-001 Phase 1 Success in Glanzmann Thrombasthenia Showcased at EAHAD 2024
29 May 2024
HMB-001, a novel bispecific antibody developed by Hemab Therapeutics, has shown promising results in Phase 1 clinical trials for treating Glanzmann Thrombasthenia.
Read →
Anixa Begins Higher Dose Phase in Ovarian Cancer CAR-T Trial
Pharma Pioneer
2 min read
Anixa Begins Higher Dose Phase in Ovarian Cancer CAR-T Trial
29 May 2024
Anixa Biosciences has initiated treatment for a fourth participant in its Phase 1 clinical trial for a new CAR-T cell therapy aimed at ovarian cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.